CRISPR NEWS

The PTAB initiates the interference

The U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) declares an interference on the use of CRISPR-Cas9 for gene editing in eukaryotic cells between the allowed claims of a patent application of the Doudna-Charpentier team, and 12 patents of the Broad. In a “first-to-invent” system, which prevailed in the United States until March 15, 2013, the PTAB conducts an interference process to determine who was first to invent when two or more parties file applications for overlapping subject matter. As the first to file, the Doudna-Charpentier team is the senior party in the proceeding, and the Broad is the junior party. In an interference, the senior party has an advantage as the presumed prior inventor. (Since March 15, 2013, the US is now on a first-to-file system, which is the same as the rest of the world.)

 

Download the PTAB Declaration of Interference

LATEST

Sign up to receive updates from the CRISPR Collective

Related News

U.S. Patent and Trademark Office issued U.S. Patent No. 10,266,850 (‘the ‘850 patent), to The Regents of the University of California, the University of Vienna, and Dr. Emmanuelle Charpentier
European Patent Office (EPO) awarded the Doudna-Charpentier team a broad CRISPR-Cas9 patent (EP Patent No. 3 401 400)
U.S. patent office issued third CRISPR patent to CVC; indicates it will issue a fourth
Read moreArrow-down